Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Continuing Allston Troubles Mean Another Brief Shutdown, Delay For Lumizyme Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

An FDA "complete response" letter in relation to Genzyme's sBLA for Lumizyme says plant problems must be resolved before approval.
Advertisement

Related Content

FDA Inspection Of Genzyme Plant Finds Lack Of Follow-up, Old Equipment, Poor Personnel Qualification
FDA Inspection Of Genzyme Plant Finds Lack Of Follow-up, Old Equipment, Poor Personnel Qualification
American Heart Association Scientific Sessions, In Brief
American Heart Association Scientific Sessions, In Brief
More Bad News For Genzyme: This Time, A Phase II/III Phosphate Binder Disappoints
More Bad News For Genzyme: This Time, A Phase II/III Phosphate Binder Disappoints
Genzyme, FDA Warn Of Foreign Particles Found In Some Lots Of Five Drugs
Genzyme Plant Cleanup Brings Temporary Halt To Fabrazyme, Cerezyme Production

Topics

Advertisement
UsernamePublicRestriction

Register

PS068752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel